Hammani Tech Test



Clinicians familiar with OGT provide specialized medical knowledge and compassionate care to ensure the best quality of life for our community members.

Mischa Larson


Sahar Heaton


Oscar Edwards

How We Work

We Complete Every Step Carefully

Your support of the OGT Foundation fuels groundbreaking research into O-GlcNAcylation, paving the way for transformative treatments and a healthier future.


Volunteer your time

We need community members and parents willing to become involved with our organization.


Join the Board

We are continually looking for additional individuals willing to serve on our Medical Advisory Board.


Share your story

Inspire other families, researchers and clinitians by sharing a personal story.


Join our community

Help raise awareness of OGT Foundation by joining and participating in our activities.

Eva Morava MD PhD

Professor of Medical Genetics; Consultant

Department of Clinical Genomics-Department of Laboratory Medicine and Pathology, Mayo Foundation for Medical Education and Research

Eva Morava-Kozicz, M.D., Ph.D., conducts translational research in mitochondrial disorders and congenital disorders of glycosylation (CDGs). Dr. Morava is actively involved in developing dietary therapies in genetic disorders and is the principal investigator of a multicenter study on the natural history of CDG.

Focus areas

  • Diagnostics therapy and follow-up of mitochondrial disease. Dr. Morava’s modified scoring system has been used for more than 10 years to diagnose mitochondrial disease. It is now being adapted for the next-generation sequencing era to discover novel types of mitochondrial disorders, including the novel group of phospholipid synthesis defects.
  • Discovering new congenital disorders of glycosylation. Using next-generation sequencing, Dr. Morava played a crucial role in the definition of ATP6V0A2-CDG, SRD5A3-CDG, SLC35A1-CDG, ATP6V1A-CDG, ATP6V1E1-CDG and PGM1-CDG. She was also involved in the discovery of DPM2-CDG, DPM1-CDG, COG7-CDG, MAN1B1-CDG, ATP6VAP1-CDG, CCDC115-CDG and TMEM199-CDG, and is currently involved in unsolved disease discovery.
  • Developing therapies for CDGs. Dr. Morava is involved in evaluating therapies in CDGs, including transplantation and dietary therapies such as D-galactose therapy. She is investigating the D-galactose working mechanism and is involved in clinical trials of many types of CDGs. Dr. Morava is working in close collaboration with the patient associations United Mitochondrial Disease Foundation (UMDF) and CDG CARE.
  • Defining the new syndrome group of metabolic cutis laxa. Previously called ARCL type 2A, metabolic cutis laxa is a connective tissue disorder that causes premature aging. Dr. Morava first described the glycosylation abnormalities in ARCL type 2A, and defined the characteristic phenotype of the new disease, metabolic cutis laxa. Since then, several new inborn errors have been found with different metabolic abnormalities.

Links and key research papers